Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines—iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics—with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.
Critical care, hospital wards, outpatient, home management
Core Products
iNOwill – Inhaled Nitric Oxide Therapy
Feature
Detail
Technology
World’s first electrochemical catalysis iNO therapy device
Regulatory Status
NMPA approved (2022); CE marked (EU, 2025)
Indication
Acute critical care of severe cardiopulmonary diseases (pulmonary hypertension)
Differentiation
Electrochemical catalysis method vs. traditional cylinder‑based delivery
NovaPulse Intra‑Aortic Balloon Pump (IABP)
Feature
Detail
Technology
First domestically manufactured pneumatic IABP in China
Regulatory Status
NMPA approved for marketing
Clinical Settings
Operating rooms, ICUs, catheterization labs
Indication
Temporary mechanical circulatory support for cardiovascular and perioperative care
Strategic Implications
Critical Care Focus: Novlead’s iNO therapy and mechanical circulatory support products address high‑acuity, life‑threatening conditions with limited effective alternatives, supporting premium pricing and hospital formulary priority.
Domestic Manufacturing Advantage:First domestically produced pneumatic IABP reduces import dependence and aligns with China’s medical device localization policies, potentially securing procurement preferences in public hospitals.
Electrochemical Innovation:iNOwill’s electrochemical catalysis eliminates cylinder storage and logistics challenges, enabling point‑of‑care NO generation with improved safety and workflow efficiency.
IPO Growth Capital:Hong Kong listing provides international investor access and capital for pipeline expansion, including exhaled breath diagnostics for non‑invasive disease monitoring.
Market Context
Factor
Impact
iNO Therapy Market
~ $500 million globally; pulmonary hypertension and hypoxic respiratory failure in neonates/ICU settings
IABP Market
~ $400 million; dominated by Maquet (Getinge) and Teleflex; domestic Chinese production disrupts import‑dependent market
Critical Care Device Growth
Post‑pandemic ICU investment surge; China expanding critical care infrastructure in tier‑2/3 cities
Breath Diagnostics Opportunity
Exhaled NO and volatile organic compound analysis emerging for asthma, COPD, and infectious disease screening
Forward‑Looking Statements This brief contains forward‑looking statements regarding IPO pricing, listing timeline, and commercial expansion for Novlead’s product portfolio. Actual results may differ due to risks including Hong Kong market volatility, competitive device launches, and regulatory inspection outcomes for manufacturing facilities.-Fineline Info & Tech
By Fineline Cube 